Disclosed are methods for preparing cannabigerol (CBG) or a CBG analog, embodiments of the method comprising providing a compound (I); combining the compound (I) with geraniol and a solvent to form a reaction mixture; and combining the reaction mixture with an acid catalyst to form a product mixture comprising the CBG or the CBG homolog. The method may further comprise separating the CBG or the CBG analog from the product mixture and may further comprise purifying the CBG or CBG analog. Methods for preparing cannabigerolic acid (CBGA) or a cannabigerolic acid analog are also disclosed. The present disclosure also provides highly purity CBG, CBGA, and analogs thereof.

This invention is for improving the manufacturing pharmaceutical grade CBD and other cannabinoids following current Good Manufacturing Practices (cGMP) of the US FDA for use in clinical trials for CNS and other indications by the NIH and other researchers. The major cannabinoids in marijuana (Cannabis) and hemp originate from Cannabigerolic Acid (CBGA) present in the biomass of the plant. Plant enzymes that are specific to different strains of biomass converts CBGA to different carboxylic acids of cannabinoids including Cannabidiolic Acid (CBDA) and Δ9-Tetrahydrocannabinolic Acid (Δ9-THCA). These are relatively stable in the growing and fresh-cut plants. These are converted by thermal decarboxylation to Cannabidiol (CBD) and Δ9-Tetrahydrocannabinol (Δ9-THC), carbon dioxide and water. Cannabinoids can be manufactured by first heating the Cannabis biomass to convert carboxylic acids prior to extraction and purification. Alternatively, and preferably because of manufacturing cost and product stability, the carboxylic acids can be first extracted and purified. They can be utilized in the carboxylic acid form or stored in a stable manner until converted to cannabinoids for use in medicine. This invention provides an efficient method for their conversion utilizing a high-pressure reactor under inert conditions.

This invention is for improving the manufacturing pharmaceutical grade CBD and other cannabinoids following current Good Manufacturing Practices (cGMP) of the US FDA for use in clinical trials for CNS and other indications by the NIH and other researchers. The major cannabinoids in marijuana (Cannabis) and hemp originate from Cannabigerolic Acid (CBGA) present in the biomass of the plant. Plant enzymes that are specific to different strains of biomass converts CBGA to different carboxylic acids of cannabinoids including Cannabidiolic Acid (CBDA) and Δ9-Tetrahydrocannabinolic Acid (Δ9-THCA). These are relatively stable in the growing and fresh-cut plants. These are converted by thermal decarboxylation to Cannabidiol (CBD) and Δ9-Tetrahydrocannabinol (Δ9-THC), carbon dioxide and water. Cannabinoids can be manufactured by first heating the Cannabis biomass to convert carboxylic acids prior to extraction and purification. Alternatively, and preferably because of manufacturing cost and product stability, the carboxylic acids can be first extracted and purified. They can be utilized in the carboxylic acid form or stored in a stable manner until converted to cannabinoids for use in medicine. This invention provides an efficient method for their conversion utilizing a high-pressure reactor under inert conditions.

This invention is directed to compounds, compositions, and methods to treat metabolic diseases. For example, the invention is drawn to compounds identified in extracts from Artemisia scoparia for the treatment of metabolic disease.

This invention is directed to compounds, compositions, and methods to treat metabolic diseases. For example, the invention is drawn to compounds identified in extracts from Artemisia scoparia for the treatment of metabolic disease.

The novel water-soluble salts of cannabinoids with increased bioavailability, their preparation and uses.

The novel water-soluble salts of cannabinoids with increased bioavailability, their preparation and uses.

Disclosed herein are embodiments of a method for making substituted compounds with specific and selectable regiochemistry. Also disclosed are compounds made by the method. The method may comprise contacting a compound having a formula I

##STR00001##

with a compound according to formula II

##STR00002##

in the presence of a Lewis acid to form a phenol compound according to formula III and/or a benzofuranone compound according to formula IV

##STR00003##

Disclosed herein are embodiments of a method for making substituted compounds with specific and selectable regiochemistry. Also disclosed are compounds made by the method. The method may comprise contacting a compound having a formula I

##STR00001##

with a compound according to formula II

##STR00002##

in the presence of a Lewis acid to form a phenol compound according to formula III and/or a benzofuranone compound according to formula IV

##STR00003##

Systems and methods for the treatment of plants, including decarboxylation, photo-oxidation, oxidation and/or combinations thereof, of cannabis and hemp plants and oils for biosynthesizing THCA, CBDA, and CBCA from CBGA are disclosed. A cannabinoid compound solution is fed into a cavitation zone of a controlled cavitation apparatus where the cannabinoid compound solution is subjected to cavitation and interaction with UV light for conversion of the cannabinoid compound solution to form a synthesized cannabinoid THC, CBD, CBC, CBG, CBNA, CBEA, CBLA product, or combinations thereof.